Roche secures Zealand obesity drug candidate for up to $5.3 billion
Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...
Hosted on MSN23d
Zealand Pharma steadfastly upholds amylin-based obesity drug strategy
Zealand Pharma’s search for a partner for its amylin-based obesity therapy petrelintide remains ongoing, with no agreement announced in its 2024 earnings report. The company has yet to secure a ...
pharmaphorum4d
Amylin Pharmaceuticals bought by Bristol-Myers, expanding diabetes alliance with AstraZeneca
Bristol-Myers Squibb Co. has announced it will acquire Amylin Pharmaceuticals for approximately US $5.3 billion in cash. Following the completion of this acquisition, Bristol-Myers Squibb will ...
MedCity News13d
AbbVie Enters Obesity Field, Paying $350M for Amylin Receptor Agonist Already in the Clinic
The Gubra drug a peptide engineered to be an analog for amylin, a hormone that helps regulate blood sugar and food intake. It is specifically designed to bind to and activate amylin and calcitonin ...
BioWorld13d
Abbvie enters $2.2B deal for Gubra’s amylin obesity drug
In addition, there will be a $350 million up-front payment as Abbvie takes over the reins of GUB-014295 (referred to as Gubamy), a long-acting analog of the satiety hormone amylin, currently in phase ...
Yahoo Finance13d
AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity
Agreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie's global infrastructure for developing and commercializing therapies for ...
pharmaphorum1d
BMS completes acquisition of Amylin, AZ buys equal share
It has been announced that following Bristol-Myers Squibb’s (BMS) successful acquisition of Amylin Pharmaceuticals, AstraZeneca (AZ) has made an initial payment of approximately US $3.2 billion ...
Nature5y
Amylin's $1 billion heavyweight deal
In November, Amylin announced a $1 billion partnership with Osaka, Japan–based Takeda to codevelop and commercialize obesity treatments. Takeda paid the San Diego–based biotech $75 million ...
Yahoo Finance13d
ABBV Enters Obesity Bandwagon, Inks $2.2B Licensing Deal for Amylin Drug
AbbVie ABBV announced that it has entered into a licensing agreement with Denmark-based biotech Gubra for the latter’s experimental obesity drug, GUB014295. This marks the American drugmaker’s ...
Nasdaq13d
AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity
GUB014295 is currently in a Phase 1 clinical trial. A potential long-acting amylin analog, GUB014295 is an agonist that specifically activates amylin and calcitonin receptors. Amylin, a satiety ...
The Victoria Advocate13d
AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity
Partnership marks AbbVie's entrance into the obesity field Agreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie's global ...